Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Infergen interferon alfacon-1: Marketed

In an open-label, German physician-sponsored study, 24 of 50 (48%)

Read the full 108 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE